The study failed to show a significant reduction in tumor volume with dasatinib treatment, suggesting inhibition of SRC as well as other SFKs, including BLK and LCK alone, is insufficient to kill DSRCT bulk tumors. The gene discussed is BLK; the disease is neoplasm.